Wealth Enhancement Advisory Services LLC boosted its holdings in Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 18.7% in the first quarter, HoldingsChannel reports. The institutional investor ...

Shares of Haleon PLC HLN slid 1.51% to £3.78 Thursday, on what proved to be an all-around positive trading session for the ...

Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl ...

Expert Sales Operations.Paritosh Gupta shared the news of his new role via LinkedIn, stating, "I’m delighted to share that ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock and why I recommend a sell rating.

See the latest Haleon PLC ADR stock price (HLN:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

“Now you can give more information, and trustworthy information,” Shaikh says. “Haleon is leading the way in doing this.” Shaikh hopes more companies will follow Haleon’s lead and use technology to ...

Haleon has quite a good cash flow conversion, as the brand investments and expansion don’t seem to tie up a lot of capital. With the discussed estimates along with a cost of capital of 7.20%, ...

Haleon HLN-0.75 % decrease; red down pointing triangle posted a higher pretax profit for 2024 despite lower revenue, and said it expected further organic revenue and profit growth this year.

Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company's CEO Brian McNamara told Reuters on Tuesday.